A Single-center, Multi-arm, Open-label, Randomized, 3-period, Crossover, Phase 1 Study to Evaluate the DDI, PK, Safety, and Tolerability of Single Doses of SPR741 Co-administered With Three Different Antibiotics in Healthy Volunteers
Latest Information Update: 14 Dec 2022
At a glance
- Drugs SPR 741 (Primary) ; Aztreonam; Ceftazidime; Tazobactam
- Indications Gram-negative infections
- Focus Pharmacokinetics
- Sponsors Spero Therapeutics
- 01 Jul 2019 Results from SPR741-101s and SPR741-102 studies were published in the Antimicrobial Agents and Chemotherapy.
- 28 Aug 2018 According to a Spero Therapeutics media release, the company expects that data from a phase 1 clinical trial of SPR206 (298950) together with the data from this completed trial (SPR741) will enable the selection of a lead candidate from the Potentiator Platform to move forward into late stage development.
- 23 May 2018 Results presented in a Spero Therapeutics media release.